Q-omics provides the consensus-scored KRT8P13 profile across patient tissues and cancer cell-line models. KRT8P13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KRT8P13 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, KRT8P13 RNA expression shows 16,719 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, and GBM as cancer lineages where KRT8P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT8P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT8P13 survival associations across molecular data types. KRT8P13 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT8P13 RNA expression–survival associations across cancer types. High KRT8P13 expression shows unfavorable associations in LUAD, KIRC, LIHC and ACC, but favorable associations in PRAD and READ. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KRT8P13 RNA expression.
This table summarizes KRT8P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT8P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT8P13 shows lower tumor expression in THCA and higher tumor expression in LUAD, KIRP, LUSC, STAD and CHOL. The LUAD box plot shows higher KRT8P13 RNA expression in tumor versus normal tissue (log2 FC = +0.168, t-test p = .003).
This table shows molecular features associated with KRT8P13 in patient tissues and cancer cell lines. In patient samples, KRT8P13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
